1. Home
  2. SVV vs NVAX Comparison

SVV vs NVAX Comparison

Compare SVV & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Savers Value Village Inc.

SVV

Savers Value Village Inc.

N/A

Current Price

$10.28

Market Cap

1.4B

ML Signal

N/A

Logo Novavax Inc.

NVAX

Novavax Inc.

N/A

Current Price

$10.32

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SVV
NVAX
Founded
1954
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
SVV
NVAX
Price
$10.28
$10.32
Analyst Decision
Buy
Hold
Analyst Count
6
9
Target Price
$13.67
$11.33
AVG Volume (30 Days)
2.1M
4.9M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
309.76
EPS
0.10
N/A
Revenue
$1,678,954,000.00
$1,123,479,000.00
Revenue This Year
$6.91
N/A
Revenue Next Year
$7.80
N/A
P/E Ratio
$102.50
N/A
Revenue Growth
9.19
64.69
52 Week Low
$6.91
$6.20
52 Week High
$13.89
$11.85

Technical Indicators

Market Signals
Indicator
SVV
NVAX
Relative Strength Index (RSI) 47.91 72.89
Support Level $10.24 $8.42
Resistance Level $10.70 $10.90
Average True Range (ATR) 0.34 0.56
MACD -0.11 0.20
Stochastic Oscillator 31.11 84.11

Price Performance

Historical Comparison
SVV
NVAX

About SVV Savers Value Village Inc.

Savers Value Village Inc is a for-profit thrift operator in the United States and Canada. It purchases second-hand textiles (i.e., clothing, bedding, and bath items), shoes, accessories, housewares, books, and other goods from its non-profit partners (NPPs), either directly from them or via on-site donations (OSDs) at Community Donation Centers at its stores. The company then processes, selects, prices, and sells these items in its stores.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: